[Manifestations of the antinociceptive and anxiolytic properties of the compound GB-115: interactions of cholecystokinin and opioid systems].
The antinociceptive and anxiolytic properties of the new drug GB-115 (0.0125-4 mg/kg, i.p.), which is a short peptide antagonist of CCK2-receptors, have been studied in rats and mice using thermal models of nociception and the standard "elevated plus-maze" (EPM) test for measuring anxiety. It s established that GB-115 (4 mg/kg) significantly increases the response latency in naloxone-independent manner in the "hot plate" test in mice and produced a moderate naloxone-reversible analgesic effect in the "tail flick" test in mice. The blocking of opioid receptors by naloxone does not influence the anxiolytic effects of GB-115 (0.025 and 4 mg/kg) in the EPM test on rats. It has been suggested that GB-115 produced anxiolytic acting on CCK2-receptors, and its role in the control of pain perception is manifested through the interaction with opioidergic mechanisms on a spinal level rather than with non-opioid mechanisms on a supraspinal level.
Kolik
L G
LG
Zhukov
V N
VN
Seredenin
S B
SB
D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004151:Dipeptides / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology*; D010147:Pain Measurement; D051381:Rats; D043887:Receptor, Cholecystokinin B / Q000037:antagonists & inhibitors*
D000700:Analgesics; D014151:Anti-Anxiety Agents; D004151:Dipeptides; C520797:GB-115; D043887:Receptor, Cholecystokinin B; D009270:Naloxone